Thanks, I did a bit more research and realised the future royalties is where the value is for Brickell. I also read that the product was no longer in line with Brickell's strategic direction of product development, hence the desire to sell.
Ann: BOT Submits FDA New Drug Application for Sofpironium Bromide, page-44
-
- There are more pages in this discussion • 129 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.015(3.95%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 37.5¢ | 35.0¢ | $1.511M | 4.151M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 61200 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 201952 | 4 |
View Market Depth
| Last trade - 10.07am 15/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |